June 13, 2016
Cambridge, MA

Multiple Charities Join Solid to Defeat Duchenne muscular dystrophy

Solid is proud to announce that three leading charities from around the world, Duchenne Now, Save Our Sons and Fight DMD, have joined our fight to solve Duchenne muscular dystrophy (DMD) and improve the lives of patients.  The generous grants provided by these organizations will directly fund our research programs to find new breakthroughs in DMD treatment. 

The grants include:

Duchenne Now: The U.K.-based organization founded by Tony Levene, Vici Richardson and Paul Fitzpatrick has committed a one-time grant of $150,000 to fund our Disease Modifying Therapy programs targeted at managing the symptoms associated with disease progression.

Fight DMD: Founded by Terry Marlin in Tennessee USA, the organization has committed $100,000 dollars over two years to fund efforts within our Solid GT program to identify next generation technologies that may restore dystrophin protein expression in the body.

Save Our Sons: The Australian organization founded by Elie Eid has committed $400,000 Australian Dollars over two years to fund different efforts within our Disease Modifying Therapy and Solid GT programs, including the development of potential symptomatic therapies, certain aspects of our AAV-associated micro-dystrophin gene therapy program and our ongoing efforts to uncover new technologies that may restore dystrophin expression.

“I want to give special thanks to each of the children for which these charities were formed – Emilio, Joey, Josh, Zak, Raul, Jonah and Emory,” said Annie Ganot, head of Patient Advocacy at Solid Biosciences.  “It is you and your families who inspire us every day in our work to develop treatments for all boys and young men with Duchenne muscular dystrophy.”

This is the first time that Duchenne Now, Save Our Sons and Fight DMD have contributed grants to Solid Biosciences.  As part of our commitment to partnership and transparent communication, Solid will provide each organization with regular updates to show our work and progress.

If you are a charity and would like to partner with Solid on ongoing projects,

Click Here

Related news


Solid Biosciences is proud to join the global rare disease community again this year to observe Rare Disease Day


Today we are excited to announce the initiation of our first clinical trial for SGT-001.


Phase I/II adaptive clinical trial to evaluate safety and efficacy in ambulatory and non-ambulatory children and adolescents.


Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. 


New data from the SGT-001 preclinical program was published today in Molecular Therapy – Methods and Clinical Development


We are getting ready to initiate a clinical study for our gene transfer candidate, SGT-001, later this year.


Solid Biosciences is pleased to announce additional research grant from our Australia-based partner Save Our Sons and an initial research grant from Ireland-based Join Our Boys.

  • Jennifer Ziolkowski, CPA, joins as Chief Financial Officer.
  • Carl Morris, Ph.D., promoted to Chief Scientific Officer.
  • Joel Schneider, Ph.D., promoted to Chief Technology Officer, Head of Exploratory R&D.

Company to Use Proceeds to Advance Programs for Duchenne Muscular Dystrophy.


Solid Biosciences is proud to join the global Rare Disease community to recognize Rare Disease Day 2017.


More information about Solid?

Please subscribe to receive our latest news